Davis Polk advised  the representatives of the several underwriters in connection with the $150 million initial public offering of 10,000,000 shares of common stock of Aligos Therapeutics, Inc. at $15.00 per share. Aligos’ common stock is listed on the Nasdaq Global Select Market under the symbol “ALGS.”

Aligos is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the development of targeted antiviral therapies for chronic hepatitis B and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis. Aligos Therapeutics is headquartered in South San Francisco, California.

The Davis Polk corporate team included partner Alan F. Denenberg and associates Tierney O’Rourke and Sylvia Zaich. Partner Michael Farber provided tax advice. Partner David R. Bauer and associates Daniel P. Kearney, Hilary Smith and Brette L. Trost provided intellectual property advice. Counsel Marcie A. Goldstein provided FINRA advice. Associate Sijia Cai provided 1940 Act advice. Members of the Davis Polk team are based in the Northern California and New York offices.